KCA
Search
- Page Path
- HOME > Search
Original Articles
- Breast cancer
- Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
- Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung
- Cancer Res Treat. 2023;55(2):542-550. Published online September 8, 2022
- DOI: https://doi.org/10.4143/crt.2022.834
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker. -
Citations
Citations to this article as recorded by
- The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li
Histopathology.2025;[Epub] CrossRef - Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef - Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
Scientific Reports.2024;[Epub] CrossRef - Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef - Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef - Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Discover Oncology.2023;[Epub] CrossRef
- The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
- 5,461 View
- 178 Download
- 6 Web of Science
- 6 Crossref
- Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization
- Kwang Hyun Baek, Min Eui Hong, Yoon Yang Jung, Chung Hun Lee, Tae Jin Lee, Eon Sub Park, Mi Kyung Kim, Jae Hyung Yoo, Soo Whan Lee
- Cancer Res Treat. 2012;44(1):50-56. Published online March 31, 2012
- DOI: https://doi.org/10.4143/crt.2012.44.1.50
-
Abstract
PDFPubReaderePub
- PURPOSE
The androgen receptor (AR) plays a central role in prostate cancer. Evidence from several groups indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) may enhance AR activity in prostate cancer cell lines. This study was designed to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR and HER2 genes are amplified in prostate cancer tissues.
MATERIALS AND METHODS
The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate cancer samples were investigated by immunohistochemical analysis and chromogenic in situ hybridization was used to determine whether the EGFR and HER2 genes were amplified in these tissues.
RESULTS
The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively, but their expression levels were not significantly associated with clinicopathologic factors. Of the cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues in which EGFR protein was expressed. HER2 expression was detected in only 1 case (1.5%). No amplification of the EGFR or HER2 genes was found in prostate cancer specimens.
CONCLUSION
This study was limited by small number of subjects, but it can still be inferred that the expression levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients. The potential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study. -
Citations
Citations to this article as recorded by- The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study
Michalis Liontos, Anna Goussia, Nikolaos Korfiatis, Kyriaki Papadopoulou, Georgios Kanellis, Anastasios Visvikis, Georgios Petrakis, Marinos Tsiatas, Elena Fountzilas, Epaminontas Samantas, George Fountzilas, Eleni Efstathiou
Clinical Genitourinary Cancer.2025; 23(1): 102253. CrossRef - Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics
Nicole Mavingire, Janelle C. Moore, Jabril R. Johnson, Abdulrahman M. Dwead, Cheryl D. Cropp, Yehia Mechref, Firas Kobeissy, Soroush Rais-Bahrami, Leanne Woods-Burnham
Cancers.2024; 16(19): 3262. CrossRef - Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, Parthasarathy Seshacharyulu
Expert Opinion on Therapeutic Targets.2023; 27(4-5): 305. CrossRef - The association of claudin-18 and androgen receptor expression in prostatic carcinoma: an immunohistochemical study
Heba M. Rashad, Hanan Ahmed, Kareem Ali El Attar, Eman A. Saad
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef - Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods
Mohd Mabood Khan, Mohammad Taleb Mohsen, Md. Zubbair Malik, Sali Abubaker Bagabir, Mustfa F. Alkhanani, Shafiul Haque, Mohammad Serajuddin, Mausumi Bharadwaj
Genes.2022; 13(4): 655. CrossRef - FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation
Tao Zhou, Tingting Chen, Bin Lai, Wenfeng Zhang, Xi Luo, Ding Xia, Weihua Fu, Jie Xu
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef - The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples
Simon Stücheli, Selene Araya, Caner Ercan, Seraina O. Moser, John Gallon, Paul Jenö, Salvatore Piscuoglio, Luigi Terracciano, Alex Odermatt
Cancers.2022; 14(13): 3074. CrossRef - Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate
Wan-fu Wu, Li Wang, Nicholas Spetsieris, Myrto Boukovala, Eleni Efstathiou, Clemens Brössner, Margaret Warner, Jan-Ake Gustafsson
Proceedings of the National Academy of Sciences.2021;[Epub] CrossRef - Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality
Sylvie Clairefond, Véronique Ouellet, Benjamin Péant, Véronique Barrès, Pierre I. Karakiewicz, Anne-Marie Mes-Masson, Fred Saad
Cancers.2021; 13(7): 1688. CrossRef - Evaluating the effect of secretome of human amniotic mesenchymal stromal cells on apoptosis induction and epithelial‐mesenchymal transition inhibition in LNCaP prostate cancer cells based on 2D and 3D cell culture models
Fatemeh Safari, Termeh Shakery, Nadiya Sayadamin
Cell Biochemistry and Function.2021; 39(6): 813. CrossRef - The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
Guilherme Peixoto, Fernando Korkes, Cristiano Pazeto, Marilia De Castro, Thiago Lima, Marcelo Wroclawski, Nicolle Christofe, Marcos Tobias‑Machado, Lucila Santiago, Sidney Glina
Molecular and Clinical Oncology.2021;[Epub] CrossRef - Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR—A Potential Therapeutic Target
Nomi Zalcman, Mijal Gutreiman, Tal Shahar, Michael Weller, Iris Lavon
International Journal of Molecular Sciences.2021; 22(20): 10954. CrossRef - Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma
Guang-Qian Xiao, Elise Nguyen, Pamela D. Unger, Andy E. Sherrod
Experimental and Molecular Pathology.2020; 114: 104400. CrossRef - Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells
Julie Schmitt, Shanlong Huang, Elliot Goodfellow, Christopher Williams, Bertrand J. Jean-Claude
Journal of Medicinal Chemistry.2020; 63(11): 5752. CrossRef - EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality
Tingting Chen, Jie Xu, Weihua Fu
Frontiers in Oncology.2020;[Epub] CrossRef - KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature
Atike Bahcivan, Mehmet Gamsizkan, Sinem Kantarcioglu Coskun, Sengul Cangur, Alpaslan Yuksel, Aysegul Ceyhan, Binnur Onal
The Aging Male.2020; 23(5): 1627. CrossRef - Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis
Laura Foj, Xavier Filella
Pathology & Oncology Research.2019; 25(4): 1445. CrossRef - Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma
Atif Ali hashmi, Shumaila Kanwal Hashmi, Muhammad Irfan, Huda Asif, Laila Nisar, Maheen Naeem, Erum Yousuf Khan, Samina Baloch, Naveen Faridi
Applied Cancer Research.2019;[Epub] CrossRef - 3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines
Kailei Xu, Kavya Ganapathy, Thomas Andl, Zi Wang, John A. Copland, Ratna Chakrabarti, Stephen J. Florczyk
Biomaterials.2019; 217: 119311. CrossRef - Correlation of Gleason Grading and Prognostic Immunohistochemistry Markers (Human Epidermal Growth Factor Receptor 2/neu and Androgen Receptor) in Prostatic Core Needle Biopsy: A Study in a Tertiary Care Center
Utsha Senapati, Moumita Sengupta, Chhanda Datta, Uttara Chatterjee, Dilip Kumar Pal, Diya Das, Piyali Poddar
Indian Journal of Medical and Paediatric Oncology.2019; 40(02): 201. CrossRef - Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients
Hamdy E. A. Ali, Pei-Yau Lung, Andrew B. Sholl, Shaimaa A. Gad, Juan J. Bustamante, Hamed I. Ali, Johng S. Rhim, Gagan Deep, Jinfeng Zhang, Zakaria Y. Abd Elmageed
Scientific Reports.2018;[Epub] CrossRef - Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future Directions
Darrion L. Mitchell, Chad R. Tracy, John M. Buatti, Mark C. Smith, Anthony N. Snow, Michael D. Henry, Daniel A. Vaena, Hamed H. Tewfik, John M. Watkins
Clinical Genitourinary Cancer.2016; 14(1): 12. CrossRef - Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling
Jimeng Hu, Wenhui Zhu, Bingbing Wei, Hui Wen, Shanhua Mao, Hua Xu, Mengbo Hu, Tian Yang, Haowen Jiang
Anti-Cancer Drugs.2016; 27(10): 944. CrossRef - Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy
Takatsugu Okegawa, Naoshi Itaya, Hidehiko Hara, Mitsuhiro Tambo, Kikuo Nutahara
International Journal of Molecular Sciences.2016; 17(12): 2008. CrossRef - Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes
Geetanjali Kharmate, Elham Hosseini-Beheshti, Josselin Caradec, Mei Yieng Chin, Emma S. Tomlinson Guns, Daotai Nie
PLOS ONE.2016; 11(5): e0154967. CrossRef - HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method
Nazanin Sharifi, Arash Salmaninejad, Samira Ferdosi, Abolfazl Nesaei Bajestani, Malihe Khaleghiyan, Mehrdad Asghari Estiar, Mansour Jamali, Mohammad Reza Nowroozi, Abbas Shakoori
Oncology Letters.2016; 12(6): 4651. CrossRef - Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients
JENNIE ANDERSSON, MARIA ROSESTEDT, ANNA ORLOVA
Oncology Letters.2015; 9(2): 950. CrossRef - NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer
Chuigong Yu, Guojun Wu, Ruixiao Li, Lei Gao, Fan Yang, Yi Zhao, Jian Zhang, Rui Zhang, Jing Zhang, Libo Yao, Jianlin Yuan, Xia Li
Cancer Biology & Therapy.2015; 16(2): 287. CrossRef - MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
Richard Ottman, Camha Nguyen, Robert Lorch, Ratna Chakrabarti
Molecular Cancer.2014;[Epub] CrossRef - Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma
Shokouh Taghipour Zahir, Hamid Fallah Tafti, Koorosh Rahmani
Asian Pacific Journal of Cancer Prevention.2014; 15(15): 6425. CrossRef - ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients
Mei Qi, Xiaoqing Yang, Fan Zhang, Tao Lin, Xiubin Sun, Yanjiang Li, Huiqing Yuan, Yubo Ren, Juan Zhang, Xiaomin Qin, Bo Han, Jindan Yu
PLoS ONE.2014; 9(2): e84959. CrossRef - In vitro modeling of HER2-targeting therapy in disseminated prostate cancer
JENNIE ANDERSSON, MARIA ROSESTEDT, VERONIKA ASPLUND, NAZILA YAVARI, ANNA ORLOVA
International Journal of Oncology.2014; 45(5): 2153. CrossRef - Cell mates: paracrine and stromal targets for prostate cancer therapy
Pavel Sluka, Ian D. Davis
Nature Reviews Urology.2013; 10(8): 441. CrossRef - Bioinformatic Analysis of the Canine Genes Related to Phenotypes for the Working Dogs
Yun-Jeong Kwon, Jungwoo Eo, Bong-Hwan Choi, Yuri Choi, Jeong-An Gim, Dahee Kim, Tae-Hun Kim, Hwan-Hoo Seong, Heui-Soo Kim
Journal of Life Science.2013; 23(11): 1325. CrossRef
- The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study
- 59,576 View
- 125 Download
- 34 Crossref
First
Prev
